SCHEMBL5555811

SCHEMBL5555811

CO[C@@H]1OC(CO)(CO)[C@H]2OC(C)(C)O[C@@H]12

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20444744 1.00
SCHEMBL15489116 0.83
SCHEMBL21694344 0.82
SCHEMBL6873309 0.79
SCHEMBL5551824 0.76 ALDH1A1 (0.47)
SCHEMBL12449344 0.76 GLB1 (0.33)
SCHEMBL1716374 0.74 SMYD2 (0.32)
SCHEMBL24673045 0.72
SCHEMBL22797631 0.70
SCHEMBL22798495 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070060504-A1 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections IDENIX PHARMACEUTICALS, INC. 2007-03-15 US disclosed
US-20070060541-A1 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections IDENIX PHARMACEUTICALS, INC. 2007-03-15 US disclosed
US-20070060505-A1 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections IDENIX PHARMACEUTICALS, INC. 2007-03-15 US disclosed
US-20070060498-A1 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections IDENIX (CAYMAN) LIMITED (KY) 2007-03-15 US disclosed
US-20070060503-A1 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections IDENIX PHARMACEUTICALS, INC. 2007-03-15 US disclosed
US-20070042990-A1 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections IDENIX PHARMACEUTICALS, INC. 2007-02-22 US disclosed
US-20070037735-A1 2' and 3'-nucleoside prodrugs for treating Flaviviridae infections IDENIX PHARMACEUTICALS, INC. 2007-02-15 US disclosed
US-7138376-B2 Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides IDENIX PHARMACEUTICALS, INC. (US) 2006-11-21 US disclosed
US-7081449-B2 Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides VALEANT RESEARCH & DEVELOPMENT (US) 2006-07-25 US disclosed
US-6831069-B2 Having substituents at the C4' and C5' positions of the ribofuranose moiety; anticancer and immunomodulating effects at reduced cytotoxicity; treating autoimmune diseases, cancer, dermatitis RIBAPHARM INC. 2004-12-14 US disclosed
US-20040006007-A1 Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides IDENIX PHARMACEUTICALS, INC. 2004-01-08 US disclosed
US-20040006002-A1 Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside SOMMADOSSI JEAN-PIERRE (US) 2004-01-08 US disclosed
EP-1212326-A4 PYRROLO 2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS ICN PHARMACEUTICALS (US) 2003-08-20 EP disclosed
US-20030144502-A1 Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides MDRNA RESEARCH, INC. 2003-07-31 US disclosed
EP-1303282-A1 PYRIDO[2,3-D]PYRIMIDINE AND PYRIMIDO[4,5-D]PYRIMIDINE NUCLEOSIDES Ribapharm, Inc. (US) 2003-04-23 EP disclosed
CN-1384834-A Pyrrolo [2,3-d] pyrimidine nucleoside analoys ICN PHARMACEUTICALS (US) 2002-12-11 CN disclosed
EP-1212326-A1 PYRROLO 2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS ICN Pharmaceuticals, Inc. (US) 2002-06-12 EP disclosed
US-20020035077-A1 Pyrrolo[2,3-d]pyrimidine nucleoside analogs CEQUENT PHARMACEUTICALS, INC. 2002-03-21 US disclosed
WO-2002003997-A1 PYRIDO[2,3-D]PYRIMIDINE AND PYRIMIDO[4,5-D]PYRIMIDINE NUCLEOSIDES RIBAPHARM INC. (US) 2002-01-17 WO disclosed
WO-2001027114-A1 PYRROLO[2,3-d]PYRIMIDINE NUCLEOSIDE ANALOGS ICN PHARMACEUTICALS, INC. (US) 2001-04-19 WO disclosed